7 recruiting. 7 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Recruiting 7 |
| Phase 1 | 4 | Recruiting 4 |
Follow Systemic Sclerosis (SSc): new trials by email Literature Review of Systemic Sclerosis (SSc) trials Research Report on Systemic Sclerosis (SSc)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| FT839 in Autoimmune Diseases FT839 - ANCA-Associated Vasculitis (AAV), Idiopathic Inflammatory Myositis (IIM) | Phase 1 / Phase 2 | Recruiting | Fate Therapeutics | 446 | 2026-10-01 | 2026-09-02 |
| Controlling Hyperactive Immunity With Long-lived Lymphocytes QEL-005 - Diffuse Cutaneous Systemic Sclerosis, Rheumatoid Arthritis (RA) | Phase 1 / Phase 2 | Recruiting | Quell Therapeutics Limited | 16 | 2026-04-10 | 2026-10-19 |
| A Phase 1/2 Study of PRO-203 in Healthy Volunteers and Participants With Systemic Sclerosis. PRO-203, Placebo - Healthy Volunteers, Systemic Sclerosis (SSc) | Phase 1 / Phase 2 | Recruiting | Prolium Bioscience, Inc | 44 | 2025-10-27 | 2026-10-09 |
| AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases. Allogeneic NK Cells - Refractory Rheumatoid Arthritis (RA), Idiopathic Inflammatory Myopathies (IIMs) | Phase 2 | Recruiting | Artiva Biotherapeutics, Inc. | 90 | 2025-07-09 | 2026-07-31 |
| Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Autoimmune Diseases anti-CD19 CAR T cell therapy - Systemic Lupus Erthematosus, Systemic Sclerosis (SSc) | Phase 1 / Phase 2 | Recruiting | Peking University Third Hospital | 9 | 2025-07-01 | 2026-09-22 |
| Intralesional Injection of STS in Treatment of Calcinosis Sodium Thiosulfate (STS) - Systemic Sclerosis (SSc), Dermatomyositis | Phase 2 | Recruiting | Robyn T. Domsic, MD, MPH | 20 | 2025-03-17 | 2026-05-05 |
| BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases BCMA-CD19 CAR-T therapy - Systemic Lupus Erythematosus, Inflammatory Myopathy | Phase 2 | Recruiting | Peking University People's Hospital | 50 | 2024-12-26 | 2025-04-02 |
Scleroderma, Systemic (7) · Myositis (4) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (3) · Arthritis, Rheumatoid (3) · Scleroderma, Diffuse (3) · Sjogren's Syndrome (3) · Antiphospholipid Syndrome (2) · Dermatomyositis (2) · Lupus Erythematosus, Systemic (2) · Behcet Syndrome (1) · Calcinosis (1) · Immunoglobulin G4-Related Disease (1) · Mixed Connective Tissue Disease (1) · Polymyositis (1) · Purpura, Thrombotic Thrombocytopenic (1)
Connective Tissue Diseases (7) · Skin Diseases (7) · Skin and Connective Tissue Diseases (7) · Musculoskeletal Diseases (6) · Arthritis (5) · Autoimmune Diseases (5) · Immune System Diseases (5) · Joint Diseases (5) · Muscular Diseases (5) · Nervous System Diseases (5) · Neuromuscular Diseases (5) · Rheumatic Diseases (5) · Cardiovascular Diseases (3) · Dry Eye Syndromes (3) · Eye Diseases (3)
Artiva Biotherapeutics, Inc. (1) · Fate Therapeutics (1) · Peking University People's Hospital (1) · Peking University Third Hospital (1) · Prolium Bioscience, Inc (1) · Quell Therapeutics Limited (1) · Robyn T. Domsic, MD, MPH (1)
China (3) · United States (3) · Germany (2) · Spain (2) · Australia (1) · Brazil (1) · Bulgaria (1) · France (1) · Italy (1) · Mexico (1) · Poland (1) · Portugal (1) · Romania (1) · Serbia (1) · South Korea (1)
Michael Saddekni, M.D., PgDip, BCMAS (1) · Robyn T Domsis, MD (1) · Salim Mujais (1) · Zhanguo Li (1)
2025 (1), P50AR080612 (1)